Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernhard Scheiner

Showing results (1-10 of 203) with videos related to

Pageof 21
Sort By:
Hepatology (Baltimore, Md.)|July 2, 2025
Reply: Immortal time bias in the management of patients with HCC who achieved CR following immunotherapy-based systemic therapyBernhard Scheiner, Matthias Pinter
Alimentary Pharmacology & Therapeutics|July 18, 2019
Letter: programmed cell death protein-1-targeted immunotherapy for advanced hepatocellular carcinoma-authors' replyBernhard Scheiner, Matthias Pinter
Journal of Hepatology|January 3, 2022
Reply to: "Prognostic prediction for patients with hepatocellular carcinoma receiving immunotherapy: Are we there yet?"Bernhard Scheiner, Matthias Pinter
Alimentary Pharmacology & Therapeutics|June 28, 2019
Letter: programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort-more questions than answers. Authors' replyBernhard Scheiner, Matthias Pinter
Journal of Hepatology|February 17, 2022
Reply to: "The CRAFITY score: A new guidepost for prognosis prediction in patients with hepatocellular carcinoma undergoing immunotherapy"Bernhard Scheiner, Matthias Pinter
Journal of Hepatology|May 8, 2022
Reply to: "The CRAFITY score: a promising prognostic predictor for patients with hepatocellular carcinoma treated with tyrosine kinase inhibitor and immunotherapy combinations"Bernhard Scheiner, Matthias Pinter
Liver Cancer|February 20, 2020
Response to the Letter to the Editor Concerning the Publication "Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma"Bernhard Scheiner, Matthias Pinter
Hepatology (Baltimore, Md.)|July 7, 2025
Reply: Clarifying the impact of response criteria and locoregional therapy on complete response outcomes in patients with hepatocellular carcinoma following immunotherapyBernhard Scheiner, Matthias Pinter
Gastroenterology|January 30, 2023
Tumor-infiltrating Neutrophils: Gatekeepers in Liver Cancer Immune ControlBernhard Scheiner, David J Pinato
Journal of Hepatology|October 25, 2017
Reply to: "Acid-base disorders in liver disease"Bernhard Scheiner, Georg-Christian Funk
Pageof 21

Showing results (1-10 of 203) with videos related to

Sort By:
Pageof 21
Hepatology (Baltimore, Md.)|July 2, 2025
Reply: Immortal time bias in the management of patients with HCC who achieved CR following immunotherapy-based systemic therapyBernhard Scheiner, Matthias Pinter
Alimentary Pharmacology & Therapeutics|July 18, 2019
Letter: programmed cell death protein-1-targeted immunotherapy for advanced hepatocellular carcinoma-authors' replyBernhard Scheiner, Matthias Pinter
Journal of Hepatology|January 3, 2022
Reply to: "Prognostic prediction for patients with hepatocellular carcinoma receiving immunotherapy: Are we there yet?"Bernhard Scheiner, Matthias Pinter
Alimentary Pharmacology & Therapeutics|June 28, 2019
Letter: programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort-more questions than answers. Authors' replyBernhard Scheiner, Matthias Pinter
Journal of Hepatology|February 17, 2022
Reply to: "The CRAFITY score: A new guidepost for prognosis prediction in patients with hepatocellular carcinoma undergoing immunotherapy"Bernhard Scheiner, Matthias Pinter
Journal of Hepatology|May 8, 2022
Reply to: "The CRAFITY score: a promising prognostic predictor for patients with hepatocellular carcinoma treated with tyrosine kinase inhibitor and immunotherapy combinations"Bernhard Scheiner, Matthias Pinter
Liver Cancer|February 20, 2020
Response to the Letter to the Editor Concerning the Publication "Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma"Bernhard Scheiner, Matthias Pinter
Hepatology (Baltimore, Md.)|July 7, 2025
Reply: Clarifying the impact of response criteria and locoregional therapy on complete response outcomes in patients with hepatocellular carcinoma following immunotherapyBernhard Scheiner, Matthias Pinter
Gastroenterology|January 30, 2023
Tumor-infiltrating Neutrophils: Gatekeepers in Liver Cancer Immune ControlBernhard Scheiner, David J Pinato
Journal of Hepatology|October 25, 2017
Reply to: "Acid-base disorders in liver disease"Bernhard Scheiner, Georg-Christian Funk
Pageof 21